Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years

Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years

Abstract Introduction Psoriasis, a chronic inflammatory skin disease, affects approximately one million Canadians, with plaque psoriasis (PsO) being the most common subtype. While brodalumab has shown efficacy and safety in phase III clinical trials, Canadian real-world evidence remains limited. Thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Veronique Gaudet, Irina Turchin, Charles W. Lynde, Virginie Kelly, Dusan Sajic, Shazia Hassan, Belinda Yap, Maxime Barakat, Vimal H. Prajapati
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-03-01
Series:Dermatology and Therapy
Subjects:
Brodalumab
IL-17
Plaque psoriasis
Real-world data
Retrospective analysis
Online Access:https://doi.org/10.1007/s13555-025-01369-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01369-3

Similar Items